Junya Furukawa

Junya Furukawa

Auto-generated profile, based on publicly available information

Junya Furukawa

Department of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JFJunya Furukawa
Junya Furukawa
HKHiroomi Kanayama
Hiroomi Kanayama
HAHaruhito Azuma
Haruhito Azuma
KIKeiji Inoue
Keiji Inoue
YKYasuyuki Kobayashi
Yasuyuki Kobayashi
MFMasato Fujisawa
Masato Fujisawa

1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
HUHideto Ueki
Hideto Ueki
THTakuto Hara
Takuto Hara
YOYasuyoshi Okamura
Yasuyoshi Okamura
YBYukari Bando
Yukari Bando
TTTomoaki Terakawa
Tomoaki Terakawa
MFMasato Fujisawa
Masato Fujisawa
Ueki H, et al. Investig Clin Urol. 2022 Jul;63(4):415-424. https://doi.org/10.4111/icu.20220028

24 September 2019 in Journal of Immunotherapy
Verified
Journal Article
Closed access
KSKotaro Suzuki
Kotaro Suzuki
TTTomoaki Terakawa
Tomoaki Terakawa
JFJunya Furukawa
Junya Furukawa
KHKenichi Harada
Kenichi Harada
NHNobuyki Hinata
Nobuyki Hinata
MFMasato Fujisawa
Masato Fujisawa
Adrenal insufficiency is an extremely rare event in patients treated nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, and its detailed clinical characteristics remain unclear. The objective was to elucidate the clinical features of adrenal insufficiency related to nivolumab in patients with metastatic renal cell carcinoma (mRCC). A total of 49 consecutive patients with mRCC or unresectable renal cell carcinoma were treated with nivolumab at Kobe University Hospital between December 2016 and August 2018. Adrenal insufficiency occurred in 5 (10.2%) of these patients. We retrospectively collected the data of these 5 patients, including their clinical characteristics, clinical and laboratory findings of adrenal insufficiency, and the clinical outcome of nivolumab treatment. All cases were diagnosed with secondary adrenal insufficiency due to isolated hyposecretion of adrenocorticotropic hormone. Eosinophilia at the onset of symptoms was observed in 4 patients. No patients showed signs of hypophysitis on brain magnetic resonance imaging and the secretion of other pituitary hormones were normal in all cases. The conditions of all patients were improved by hydrocortisone replacement therapy at a physiological dose. Notably, all 5 patients showed a partial response to nivolumab and remained stable after the cessation of nivolumab. In conclusion, we described, for the first time, a case series of nivolumab-induced adrenal insufficiency in patients with mRCC. Our findings may be useful for the accurate diagnosis and the prompt treatment of this condition. In addition, there is a possibility that adrenal insufficiency may be associated with a favorable response to nivolumab in patients with mRCC.

15 June 2022 in International Journal of Urology
Verified
Journal Article
Closed access
JFJunya Furukawa
Junya Furukawa
NHNobuyki Hinata
Nobuyki Hinata
JTJun Teishima
Jun Teishima
ATAtsushi Takenaka
Atsushi Takenaka
RSRyoichi Shiroki
Ryoichi Shiroki
MFMasato Fujisawa
Masato Fujisawa

23 October 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
HUHideto Ueki
Hideto Ueki
NHNobuyki Hinata
Nobuyki Hinata
KKKoichi Kitagawa
Koichi Kitagawa
THTakuto Hara
Takuto Hara
TTTomoaki Terakawa
Tomoaki Terakawa
TSToshiro Shirakawa
Toshiro Shirakawa